<div class="docx-content">
<h3 class="text-lg font-semibold mt-6 mb-3"><strong>Chancroid (Haemophilus ducreyi) </strong><em>Based on the 2017 European BASHH/IUSTI guideline</em> </h3><h4 class="text-base font-semibold mt-4 mb-2"><strong>1. Causative Organism</strong></h4><p class="ml-4 mb-2"><em>Haemophilus ducreyi</em>: small, fastidious Gram-negative coccobacillus.Produces β-lactamase; plasmid-mediated resistance reported to tetracyclines, sulfonamides, chloramphenicol, aminoglycosides. </p><h4 class="text-base font-semibold mt-4 mb-2"><strong>2. Epidemiology &amp; Public Health</strong></h4><table><tr><td><p><strong>Aspect</strong></p></td><td><p><strong>Key facts</strong></p></td><td><p><strong>Exam pearls</strong></p></td></tr><tr><td><p>Global trend</p></td><td><p>Marked decline worldwide; still endemic pockets in <strong>North India</strong> (~24 % GUD) &amp; <strong>Malawi</strong> (~15 %). Sporadic imported cases in Europe.</p></td><td><p>Be ready to explain why lab suspicion must remain despite rarity.</p></td></tr><tr><td><p>Transmission</p></td><td><p>Sexual contact; facilitates HIV acquisition.</p></td><td><p>Male circumcision reduces risk.</p></td></tr><tr><td><p>Non-genital disease</p></td><td><p>Emerging cause of tropical cutaneous ulcers in children (South Pacific).</p></td><td><p>Distinguish from yaws in OSPE/OSCE cases.</p></td></tr></table><h4 class="text-base font-semibold mt-4 mb-2"><strong>3. Clinical Features</strong></h4><p class="ml-4 mb-2"><strong>Incubation:</strong> 3-7 days (short).<strong>Lesions:</strong> tender erythematous papule → pustule → soft, painful ulcer with ragged undermined edge &amp; purulent base.<strong>Lymphadenitis:</strong> unilateral, painful inguinal node in ~50 % → fluctuant bubo ± spontaneous rupture.<strong>Complications:</strong> chronic ulcers, scarring, sinus after bubo I&amp;D.<strong>No proven adverse pregnancy outcomes.</strong> </p><h4 class="text-base font-semibold mt-4 mb-2"><strong>4. Differential Diagnosis</strong></h4><p class="ml-4 mb-2"><strong>HSV</strong>, <strong>syphilis</strong>, <strong>LGV</strong>, <strong>donovanosis</strong>, <strong>traumatic/behçet ulcers</strong>.FRCPath tip: emphasise mixed infections; always test for HSV &amp; <em>T. pallidum</em>.</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>5. Diagnosis</strong></h4><table><tr><td><p><strong>Modality</strong></p></td><td><p><strong>Details</strong></p></td><td><p><strong>Strengths / Weaknesses</strong></p></td></tr><tr><td><p><strong>Clinical (probable)</strong></p></td><td><p>CDC criteria: painful ulcer + typical appearance ± inguinal LAD, negative syphilis serology/NAAT &amp; HSV NAAT/culture.</p></td><td><p>Only for surveillance; low specificity.</p></td></tr><tr><td><p><strong>Microscopy</strong></p></td><td><p>Gram stain of ulcer base.</p></td><td><p>Low sensitivity → <em>not recommended</em>.</p></td></tr><tr><td><p><strong>Culture</strong></p></td><td><p>Selective enriched media (e.g. Mueller-Hinton chocolate + vancomycin); incubate 33 °C, 5 % CO₂, &gt;3 days. Bedside inoculation best; transport at 4 °C in Amies/Stuart.</p></td><td><p>Definitive when +ve; sensitivity ≤75 %. Needed for AST.</p></td></tr><tr><td><p><strong>NAAT (preferred)</strong></p></td><td><p>In-house or multiplex PCR from ulcer swab; detects HSV &amp; <em>T. pallidum</em> simultaneously.</p></td><td><p>Highest sensitivity; viable bacteria not required; few reference labs in Europe.</p></td></tr><tr><td><p><strong>Serology</strong></p></td><td><p>Unhelpful in acute disease.</p></td><td></td></tr></table><p><strong>Specimen technique (exam favourite):</strong> vigorous swab of ulcer base after saline rinse place the swab in Amies or Stuart’s medium, keep at 4 °C, and transport rapidly.; collect pus from buboes by aspiration (lower yield), </p><h4 class="text-base font-semibold mt-4 mb-2"><strong>6. Management</strong></h4><p class="ml-4 mb-2"><strong>Patient counselling</strong>Abstain from sex until patient <strong>and</strong> partners complete therapy.Explain HIV transmission risk; offer full STI screen incl. HIV &amp; syphilis repeat at 3 months. <strong>First-line antibiotics</strong> (single-dose options)</p><table><tr><td><p><strong>Drug</strong></p></td><td><p><strong>Dose</strong></p></td><td><p><strong>Notes</strong></p></td></tr><tr><td><p><strong>Azithromycin</strong></p></td><td><p>1 g PO ×1</p></td><td><p>Safe in pregnancy, children ≥️6 m.</p></td></tr><tr><td><p><strong>Ceftriaxone</strong></p></td><td><p>250 mg IM ×1</p></td><td><p>Give to children; option in pregnancy.</p></td></tr></table><p class="ml-4 mb-2"><strong>Second-line / alternatives – preferred in HIV+ due to multiday regimens</strong></p><table><tr><td><p><strong>Drug</strong></p></td><td><p><strong>Dose</strong></p></td><td><p><strong>Restrictions</strong></p></td></tr><tr><td><p>Ciprofloxacin</p></td><td><p>500 mg PO <strong>BD ×3 days</strong></p></td><td><p>Contraindicated pregnancy, breastfeeding, &lt;18 y.</p></td></tr><tr><td><p>Erythromycin</p></td><td><p>500 mg PO <strong>QID ×7 days</strong></p></td><td><p>Use if cipro contraindicated; preferred for HIV+ pts needing multi-day Rx.</p></td></tr></table><p class="ml-4 mb-2"><strong>Bubo management</strong>Needle aspiration (may repeat) or I&amp;D under cover of antibiotics; avoid sinus formation. <strong>Follow-up</strong>Review 3–7 days: ulcers should improve within 1–2 wks.Consider treatment failure (resistance, reinfection, mis-diagnosis, immunodeficiency) if slow healing.Confirm partner notification (sexual contacts within preceding 10 days → exam &amp; treatment regardless of symptoms).No test of cure</p><p><em>H. ducreyi</em> acquired plasmid-mediated resistance to β-lactams, tetracyclines, sulfonamides, chloramphenicol &amp; aminoglycosides (1970s onward). </p><p>• Intermediate resistance to <strong>ciprofloxacin and erythromycin</strong> has been reported globally &gt; culture if fails</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>7. Laboratory / Quality &amp; Governance Points</strong></h4><p class="ml-4 mb-2"><strong>Auditable standards (≥95 %):</strong>All suspected chancroid cases undergo appropriate lab investigation (culture and/or NAAT).Partner tracing for contacts within 10 days.Offer / document HIV &amp; syphilis testing ± other STIs.Report cases to local/national surveillance systems. </p><h4 class="text-base font-semibold mt-4 mb-2"><strong>8. Exam-Level High-Yield Facts</strong></h4><p class="ml-4 mb-2"><em>H. ducreyi</em> culture ≤75 % sensitive → NAAT gold standard.Single-dose azithro / ceftriaxone equal efficacy (Ib evidence).Incubation period <strong>short</strong> vs syphilis (<strong>longer, ~21 days</strong>).Buboes ≈50 %: aspiration preferred; incision may cause persistent sinus.Consider chancroid in <strong>imported ulcers</strong>, especially if HSV &amp; syphilis negative.</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>9. Rapid Mnemonics</strong></h4><p class="ml-4 mb-2"><strong>“DUC REI”</strong> for therapy: <strong>D</strong>ucreyi → <strong>U</strong>lcer soft; <strong>C</strong>eftriaxone/<strong>C</strong>ipro, <strong>R</strong>egional nodes, <strong>E</strong>rythro/<strong>A</strong>zithro, <strong>I</strong>ncubation 3-7 days.<strong>“FAST”</strong> sample handling: <strong>F</strong>resh lesion base, <strong>A</strong>mies transport cold, <strong>S</strong>elective medium bedside, <strong>T</strong>hree-day CO₂ incubation.</p><p>These notes condense the guideline’s core messages into exam-focused points without losing essential detail. Good luck with your FRCPath preparation!</p>
</div>